# Biogen (stock symbol: BIIB) Logo in transparent PNG and SVG formats

## Biogen Logo large

### Biogen Logo large Download PNG (63.74 KB)

![Biogen Logo large Download PNG (63.74 KB)](/img/orig/BIIB_BIG-7789f89c.png)

### Biogen Logo large Download SVG (6.17 KB)

![Biogen Logo large Download SVG (6.17 KB)](/img/orig/BIIB_BIG-d3f80a9a.svg)

## Biogen Logo icon format

### Biogen Logo icon format Download PNG (204.65 KB)

![Biogen Logo icon format Download PNG (204.65 KB)](/img/orig/BIIB-c54e2f33.png)

### Biogen Logo icon format Download SVG (4.05 KB)

![Biogen Logo icon format Download SVG (4.05 KB)](/img/orig/BIIB-e2ca3719.svg)

## Biogen Logo large for dark backgrounds

### Biogen Logo large for dark backgrounds Download PNG (62.75 KB)

![Biogen Logo large for dark backgrounds Download PNG (62.75 KB)](/img/orig/BIIB_BIG.D-7f18ac4b.png)

### Biogen Logo large for dark backgrounds Download SVG (5.87 KB)

![Biogen Logo large for dark backgrounds Download SVG (5.87 KB)](/img/orig/BIIB_BIG.D-c1eec620.svg)

## About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

1. Website domain: biogen.com
2. Employees: 9610
3. Marketcap: $43.95 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
